- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate 230615-70-0
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Brinzamide intermediate
【Catalogue Number】AP0901
【CAS #】160982-16-1
【Molecular Formula】C6H6ClNO3S2
【Molecular Weight】239.7
|
Alias |
Brinzamide intermediate |
|
Catalog Number |
AP0901 |
|
CAS # |
160982-16-1 |
|
Molecular Formula |
C6H6ClNO3S2 |
|
Molecular Weight |
239.7 |
|
Structural Formula |
|
|
Product Introduction CAS 160982-16-1 |
(S) -6-chloro-3,4-dihydro-2H-thiophene [3,2-E] -1,2-thiazin-4-ol 1,1-dioxide, The English name is (S) -3,4-Dihydro-6-chloro-4-hydroxy-4H-thieno [3,2-e] -1,2-thiazine-1,1-dioxide. cas160982-16-1. This product (cas 160982-16-1) is an intermediate of brinzolamide. Brinzolamide can be used to treat primary and secondary open-angle glaucoma and ocular hypertension. It can also be used to prevent the increase of intraocular pressure after laser surgery. Can be used as a single treatment drug for patients who are ineffective against β-blockers, or have contraindications to use, or as a synergistic treatment for β-blockers. |
VIWIT 沪ICP备12014533号-2
